Asston Pharmaceuticals approved the preferential allotment of 24,10,431 equity shares at ₹115 per share on September 5, 2026. The issuance raises the company’s paid-up equity capital to ₹10.92 crore.

The Board of Directors sanctioned the allotment during a meeting that commenced at 10:30 am and concluded at 10:45 am. The shares carry a face value of ₹10 each, with a premium of ₹105 per share payable in cash.

Allotment Details

The company allotted shares to 15 investors, all categorized as public allottees. Vijay Rathee emerged as the largest recipient, acquiring 13,17,391 shares. Vijaylaxmi Infra Projects Private Limited received the second-largest allocation of 7,82,608 shares.

Consequent to this allotment, the total number of equity shares stands at 1,09,22,791. The newly allotted shares rank pari passu in all respects with existing equity shares.

What the Numbers Show

The concentration of allotment is notable, with the top two investors—Vijay Rathee and Vijaylaxmi Infra Projects Private Limited—accounting for approximately 85% of the total shares issued in this round. This suggests significant interest from specific large stakeholders rather than broad-based retail participation.

Asston Pharmaceuticals board of directors met on September 4, 2026 to approve key corporate governance changes, including the appointment of new statutory and internal auditors. The meeting also saw the re-appointment of the managing director and proposed remuneration increases for senior leadership.

The company appointed M/s Panchal S K & Associates as its statutory auditor and M/s Yash A. Jain & Associates as internal auditor. Both appointments were made subject to shareholder approval where required.

Key Governance Approvals

The board recommended the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director, who was retiring by rotation. The proposal requires approval from members at the upcoming annual general meeting.

Remuneration increases were approved for three key executives, pending member consent:

• Mr. Ashish Narayan Sakalkar, Managing Director
• Mrs. Saili Jayaram More, Whole-time Director and CEO
• Mr. Sachin Chandrakant Badakh, Non-Executive Director

Annual General Meeting Details

The company approved the notice for its 7th Annual General Meeting, scheduled for September 29, 2026 at 12:30 pm. The meeting will be conducted via Video Conferencing and Other Audio Visual Means.

M/s Pragya & Associates has been appointed as the scrutinizer for the AGM. The cut-off date for determining eligible shareholders for e-voting is set as September 22, 2026.

The board also approved the Board's Report along with all annexures, including the Management Discussion and Analysis Report forming part of the 7th Annual Report for the financial year ended March 31, 2026.